Last week the Ukrainian venture firm AVentures Capital announced it invested an undisclosed amount in Viseven, a provider of multichannel content for life sciences.
Founded by a Ukrainian team and keeping its R&D center in Ukraine, this startup now operates internationally from offices in Canada, Estonia, Russia and the USA.
Viseven develops software, mobile apps, educational virtual reality videos, and websites specifically for life science and pharmaceutical firms. Among its customers are Pfizer, Bayer, Darnitsa, and Janssen. Viseven claims its “content factory” “reduces production costs, simplify localizations and facilitate the review process.”
As a result of the investment agreement, AVentures has received a minority stake in Viseven. The other shareholers are the three co-founders, including CEO Nataliya Andreychuk.
AVentures usually invests from $500,000 to $1.5 million.
